Chardan Capital Weighs in on Krystal Biotech FY2025 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Stock analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for Krystal Biotech in a research note issued to investors on Tuesday, November 5th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of $5.78 for the year, down from their previous estimate of $8.69. Chardan Capital currently has a “Buy” rating and a $208.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.96 per share.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.67) earnings per share.

Several other brokerages also recently weighed in on KRYS. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Evercore ISI raised their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Price Performance

KRYS stock opened at $199.61 on Friday. The company has a market cap of $5.74 billion, a price-to-earnings ratio of 112.77 and a beta of 0.82. The company has a fifty day moving average price of $181.29 and a 200 day moving average price of $180.58. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in shares of Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock worth $117,189,000 after buying an additional 231,255 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after buying an additional 7,537 shares during the period. Hood River Capital Management LLC boosted its position in shares of Krystal Biotech by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares in the last quarter. Bank of New York Mellon Corp grew its position in Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock worth $35,583,000 after buying an additional 103,928 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Krystal Biotech by 11.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 176,446 shares of the company’s stock valued at $32,402,000 after buying an additional 18,021 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).